Ingemar Lagerlöf

MiniDoc is a publicly held international company based in Stockholm, Sweden, with subsidiaries in the United States, France, Germany and the United Kingdom. The company was founded in 1993 but has worked in clinical research development since the mid-1980s. MiniDoc has more experience in electronic data capture for clinical research than any company in the world. MiniDoc's business concept is to offer technology, methods, and services for clinical research activities chiefly to the pharmaceutical industry. MiniDoc can materially contribute to creating benefits in terms of time and quality in clinical trials that result in new pharmaceuticals being launched more quickly, for the benefit of patients, society, and pharmaceutical companies

CareDx International AB engages in the development, manufacture, and sale of products for transplantation of blood stem cells and organs. It offers tissue typing products and products for antibody detection. The company was founded by Ingemar Lagerlöf in 1998 and is headquartered in Stockholm, Sweden.

Allenex (Private Equity) (Allnex PE) is the private equity division of LinkMed AB (ST: LMED) in Sweden. Located in Stockholm, the firm was formerly known as LinkMed Private Equity, founded by Ingemar Lagerlöf in 1998. To assure the continued growth of their investee companies, Allnex PE has assembled a network of medical and managerial resources, divided into Corporate Operational Functions (Board and Management Team) and the Venture Management Network (Business Network and Scientific Advisory Board). The Venture Management Network provides guidance and strategic expertise to investee companies.

Olerup International AB distributes molecular diagnostic products and services for human leukocyte antigen (HLA) typing and antibody detection. It offers transplant diagnostics and supportive software. The firm provides products and services for bone marrow and organ transplantation. Its HLA portfolio consists of two product lines, Sequence Specific Primer Genomic HLA Typing and Sequencing Based Typing. The company was founded in 2009 and is headquartered in Stockholm, Sweden.

AbSorber AB develops products for allogeneic transplantation. It offers XM-ONE used for enhanced risk assessment before kidney transplantation. The firm also engages in the development of tools in transplantation. The company was founded by Jan Holgersson and Suchitra Sumitran-Holgersson in 1999 and is headquartered in Stockholm, Sweden.

AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden.

Biovator AB develops innovative, unique in vitro tests (i.e. in test tubes) which predict the risk for allergic sensitization. Many products, such as pharmaceuticals, cosmetics and food additives may be allergens, causing allergic reactions. For this reason they are tested for allergen city. Up to now such tests have been performed in laboratory animals. Biovator AB is developing two in vitro tests: the Cytokine Profile Assay (CPA) and the Gene Activation Profile Assay (GAPA). CPA will be the first allergen city test of any type, which can predict hypersensitivity reactions of the so called Type I. The Biovator technologies are well in line with EU legislative initiatives such as banning animal testing of cosmetics 2009.

IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies.

NovaHep AB provides stem-cell research for gene therapy of liver diseases. Its main area of focus is the development of biological, individualised blood vessels that can be used to replace non-functioning blood vessels in patients with different types of vascular disease. The company was founded by Suchitra Sumitran-Holgersson and Jan Anders Holgersson in 2005 and is headquartered in Gothenburg, Sweden.